FT 1101

Drug Profile

FT 1101

Alternative Names: FT1101

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator FORMA Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 12 Jan 2016 FT 1101 licensed to Celgene Corporation in European Union
  • 01 Sep 2015 Phase-I clinical trials in Acute myeloid leukaemia in USA (PO)
  • 01 Sep 2015 Phase-I clinical trials in Myelodysplastic syndromes in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top